Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics (Nasdaq: AKBA) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before market open.

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before market open. A conference call to discuss results and recent business highlights will be held on Thursday, February 26, 2026 at 8:00 a.m. EST.

Investors must register to receive dial‑in details; a live webcast and an online archive will be available via the Investors section of Akebia's website.

Market Context

This announcement sets the date of Akebia’s fourth quarter and full-year 2025 earnings call on Feb 2...

Analysis

This announcement sets the date of Akebia’s fourth quarter and full-year 2025 earnings call on Feb 26, 2026, adding to a steady flow of recent corporate and clinical updates. Prior communications highlighted Vafseo’s access to ~275,000 dialysis patients, Phase IV VOICE enrollment of >2,100 patients, and multiple Phase 2 efforts. Investors may focus on how reported financials track against the indicated Vafseo revenue range and existing trial timelines.

Key Figures

Earnings call time: 8:00 a.m. EST Dialysis access: ~275,000 patients VOICE enrollment: >2,100 patients +5 more

Earnings call time

8:00 a.m. EST

Q4 and full-year 2025 results on Feb 26, 2026

Dialysis access

~275,000 patients

Vafseo prescribing access as of Jan 12, 2026 update

VOICE enrollment

>2,100 patients

Phase IV VOICE trial completed enrollment

VOCAL enrollment

~350 patients

VOCAL study enrollment as of Jan 12, 2026

Vafseo Q4 revenue

$5–$6 million

Q4 2025 net product revenue expectation from Jan 12, 2026 update

Praliciguat FSGS sample

~60 adults

Planned enrollment for Phase 2 FSGS study

State Street ownership

13,687,561 shares (5.2%)

Schedule 13G as of 12/31/2025

Inducement options

132,675 shares at $1.41

Options granted Jan 30, 2026 to two new hires

Historical Context

5 past events · Latest: Feb 04

5 events

1. Feb 04

   Conference appearance

   24h Move

   -2.8%

   Participation in Guggenheim biotech summit with webcast access for investors.

2. Feb 02

   Inducement grants

   24h Move

   +2.2%

   Stock options granted to new hires under Nasdaq Listing Rule 5635(c)(4).

3. Jan 12

   Corporate update

   24h Move

   -7.9%

   Vafseo revenue expectations and detailed 2026 pipeline and trial timelines.

4. Jan 06

   Clinical trial start

   24h Move

   -2.6%

   First patient dosed in Phase 2 praliciguat study for FSGS.

5. Jan 05

   Inducement grant

   24h Move

   -2.6%

   New employee stock option grant with four-year vesting and 10-year term.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Akebia to Host Conference Call on February 26 at 8:00 a.m. EST

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets.

Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Akebia (AKBA) report Q4 and full year 2025 results?

Akebia will report results on Thursday, February 26, 2026 before the market opens. According to the company, the release covers the quarter and full year ended December 31, 2025 and precedes the 8:00 a.m. EST conference call.

What time is the Akebia (AKBA) earnings conference call on February 26, 2026?

The conference call is scheduled for Thursday, February 26, 2026 at 8:00 a.m. EST. According to the company, investors should dial in 15 minutes early to avoid delays and ensure timely connection.

How can investors access Akebia (AKBA) February 26, 2026 webcast and archive?

A live webcast and online archive will be available via the Investors section of Akebia's website. According to the company, the webcast can be accessed at https://ir.akebia.com/ and archived there afterward.

Do I need to register to join the Akebia (AKBA) February 26, 2026 call?

Yes, investors should register to receive dial‑in details for the call. According to the company, registering via the provided registration link supplies dial‑in information and helps avoid connection delays.

What will Akebia (AKBA) discuss on the February 26, 2026 call?

Akebia will discuss fourth quarter and full year 2025 financial results and recent business highlights. According to the company, the call will review results and provide context on recent corporate developments.